Incidence and Characteristics of Autoimmune Hepatitis
Overview
Authors
Affiliations
Background And Objectives: Autoimmune hepatitis (AIH) is a progressive inflammatory liver disease of unknown etiology, with limited population-based estimates of pediatric incidence. We reported the incidence of pediatric AIH in Canada and described its clinical characteristics.
Methods: We conducted a retrospective cohort study of patients aged <18 years diagnosed with AIH between 2000-2009 at all pediatric centers in Canada.
Results: A total of 159 children with AIH (60.3% female, 13.2% type 2 AIH) were identified. Annual incidence was 0.23 per 100000 children. Median age at presentation for type 1 was 12 years (interquartile range: 11-14) versus 10 years for type 2 (interquartile range: 4.5-13) (P = .03). Fatigue (58%), jaundice (54%), and abdominal pain (49%) were the most common presenting symptoms. Serum albumin (33 vs 38 g/L; P = .03) and platelet count (187 000 vs 249 000; P <.001) were significantly lower and the international normalized ratio (1.4 vs 1.2; P <.001) was higher in cirrhotic versus noncirrhotic patients. Initial treatment included corticosteroids (80%), azathioprine (32%), and/or cyclosporine (13%). Response to treatment at 1 year was complete in 90%, and partial in 3%. 3% of patients had no response, and 3% responded and later relapsed. Nine patients underwent liver transplantation, and 4 patients died at a mean follow-up of 4 years.
Conclusions: AIH is uncommon in children and adolescents in Canada. Type 1 AIH was diagnosed 5.5 times more frequently than type 2 AIH. Most patients respond well to conventional therapy, diminishing the need for liver transplantation.
Khendek L, Castro-Rojas C, Nelson C, Alquraish M, Karns R, Kasten J Hepatol Commun. 2024; 9(1).
PMID: 39670860 PMC: 11637754. DOI: 10.1097/HC9.0000000000000594.
Autoimmune hepatitis: Towards a personalized treatment.
Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.
PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.
B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.
Costaguta G, Alvarez F JPGN Rep. 2024; 5(3):326-333.
PMID: 39149184 PMC: 11322033. DOI: 10.1002/jpr3.12098.
Good long-term outcomes of primary sclerosing cholangitis in childhood.
Jerregard Skarby A, Casswall T, Bergquist A, Lindstrom L JHEP Rep. 2024; 6(8):101123.
PMID: 39139456 PMC: 11321284. DOI: 10.1016/j.jhepr.2024.101123.
Hahn J, Yang H, Moon J, Chang J, Lee K, Kim G EClinicalMedicine. 2023; 65:102280.
PMID: 37876996 PMC: 10590724. DOI: 10.1016/j.eclinm.2023.102280.